



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

01 April 2016
EMA/241009/2016
Procedure Management & Committees Support Division
Scientific Committee Support Department

Scientific recommendation on classification of advanced therapy medicinal products

Article 17 – Regulation (EC) No 1394/2007

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency

Brief description (or name where available) of the active substance(s)

Human amniotic membrane mesenchymal stem cells (hAMMSCs)

Brief description of the finished product

Human amniotic membrane mesenchymal stem cells in suspension

Proposed indication

Treatment of burns, scars, non-healing wounds

EMA/CAT conclusion

The committee adopted on 29th January 2016 the following scientific recommendation.

On the basis that:

- the product human amniotic membrane mesenchymal stem cells in suspension consists of engineered cells or tissues, which have been subject to substantial manipulation, so that biological characteristics, physiological functions or structural properties relevant for the intended regeneration, repair or replacement are achieved



- is administered to human beings with a view to regenerating, repairing or replacing a human tissue
the EMA/CAT considers that the Product falls within the definition of a tissue engineered product